+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Constrained Peptide Drugs Market by Peptide Type, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924951
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Constrained Peptide Drugs Market grew from USD 1.22 billion in 2023 to USD 1.47 billion in 2024. It is expected to continue growing at a CAGR of 21.44%, reaching USD 4.76 billion by 2030.

Constrained peptide drugs, also known as stapled peptides, are an emerging class of therapeutics designed to overcome limitations of traditional small molecules and biologics. They are engineered to enhance stability, bioavailability, and specificity by constraining the peptides into their active conformations. The necessity of these drugs stems from their ability to target complex diseases that require unbiased binding and high specificity, such as cancer, infectious diseases, and metabolic disorders. Their applications range from diagnostic tools to therapeutic interventions, with end-use spanning pharmaceuticals, biotechnology, and personalized medicine sectors. Market insights suggest that the rising prevalence of chronic diseases and the need for novel drug delivery mechanisms drive growth. Key influencing factors include advancements in peptide synthesis, growing investment in R&D, and increasing approval of peptide-based therapeutics by regulatory bodies. Potential market opportunities lie in personalized medicine and targeted therapies, as the specificity of constrained peptides aligns with the tailored needs of such approaches. Recommendations to seize these opportunities include investing in next-gen manufacturing technologies, optimizing delivery systems, and forging strategic collaborations with research institutions. On the downside, limitations like high production costs, complex synthesis processes, and regulatory challenges must be addressed. Furthermore, the competitive landscape, marked by the presence of established protein therapeutics, adds to market challenges. Innovation is best routed towards the development of cost-effective synthesis techniques, novel delivery platforms such as nanoparticle systems, and exploring new therapeutic areas like autoimmune diseases. Peptide conjugates and bifunctional molecules also present avenues for research and development. The constrained peptide drugs market is dynamic, with high growth potential; however, it requires a keen focus on overcoming technical and economic barriers to harness its full potential.

Understanding Market Dynamics in the Constrained Peptide Drugs Market

The Constrained Peptide Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising incidences of chronic diseases globally
    • Continuous advancements in peptide chemistry and synthesis techniques
    • Increasing demand for manufacturing of biologics and personalized medicines
  • Market Restraints
    • High cost associated with the drug development of peptides
  • Market Opportunities
    • Increasing research & development to develop novel constrained peptide drugs
    • Availability of government support for innovative therapies, including constrained peptide drugs
  • Market Challenges
    • Issues with low bioavailability of peptides

Exploring Porter’s Five Forces for the Constrained Peptide Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Constrained Peptide Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Constrained Peptide Drugs Market

External macro-environmental factors deeply influence the performance of the Constrained Peptide Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Constrained Peptide Drugs Market

The Constrained Peptide Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Constrained Peptide Drugs Market

The Constrained Peptide Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Constrained Peptide Drugs Market

The Constrained Peptide Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Constrained Peptide Drugs Market, highlighting leading vendors and their innovative profiles. These include Bicycle Therapeutics, Inc., Biosynth Ltd, IRBM S.p.A., PeptiDream Co., Ltd., Pfizer Inc., Protagonist Therapeutics, Inc., and UCB S.A.

Market Segmentation & Coverage

This research report categorizes the Constrained Peptide Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Peptide Type
    • Macrocyclic
    • Stapled
  • End-User
    • Hospitals & Clinics
    • Pharmaceutical Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of chronic diseases globally
5.1.1.2. Continuous advancements in peptide chemistry and synthesis techniques
5.1.1.3. Increasing demand for manufacturing of biologics and personalized medicines
5.1.2. Restraints
5.1.2.1. High cost associated with the drug development of peptides
5.1.3. Opportunities
5.1.3.1. Increasing research & development to develop novel constrained peptide drugs
5.1.3.2. Availability of government support for innovative therapies, including constrained peptide drugs
5.1.4. Challenges
5.1.4.1. Issues with low bioavailability of peptides
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Constrained Peptide Drugs Market, by Peptide Type
6.1. Introduction
6.2. Macrocyclic
6.3. Stapled
7. Constrained Peptide Drugs Market, by End-User
7.1. Introduction
7.2. Hospitals & Clinics
7.3. Pharmaceutical Companies
8. Americas Constrained Peptide Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Constrained Peptide Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Constrained Peptide Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. CONSTRAINED PEPTIDE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. CONSTRAINED PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. CONSTRAINED PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CONSTRAINED PEPTIDE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CONSTRAINED PEPTIDE DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY MACROCYCLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STAPLED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 16. ARGENTINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 17. ARGENTINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 18. BRAZIL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 19. BRAZIL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 20. CANADA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 21. CANADA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. MEXICO CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 23. MEXICO CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. AUSTRALIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 31. AUSTRALIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. CHINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 33. CHINA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. INDIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 35. INDIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. INDONESIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 37. INDONESIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. JAPAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 39. JAPAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. MALAYSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 41. MALAYSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. PHILIPPINES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 43. PHILIPPINES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. SINGAPORE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 45. SINGAPORE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. SOUTH KOREA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 47. SOUTH KOREA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. TAIWAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 49. TAIWAN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. THAILAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 51. THAILAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. VIETNAM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 53. VIETNAM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. DENMARK CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 58. DENMARK CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. EGYPT CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 60. EGYPT CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. FINLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 62. FINLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. FRANCE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 64. FRANCE CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. GERMANY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 66. GERMANY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. ISRAEL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 68. ISRAEL CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. ITALY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 70. ITALY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. NETHERLANDS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 72. NETHERLANDS CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. NIGERIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 74. NIGERIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. NORWAY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 76. NORWAY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. POLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 78. POLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. QATAR CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 80. QATAR CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. SPAIN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 88. SPAIN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. SWEDEN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 90. SWEDEN CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. SWITZERLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 92. SWITZERLAND CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. TURKEY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 94. TURKEY CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM CONSTRAINED PEPTIDE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. CONSTRAINED PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 100. CONSTRAINED PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Constrained Peptide Drugs Market, which are profiled in this report, include:
  • Bicycle Therapeutics, Inc.
  • Biosynth Ltd
  • IRBM S.p.A.
  • PeptiDream Co., Ltd.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • UCB S.A

Methodology

Loading
LOADING...

Table Information